Pharma Invest Devos
ActiveFrom the official registers: KBO 17 annual accounts at the National Bank publications in the Belgian Official Gazette
Summary
Pharma Invest Devos has been active since 2008 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €618,231 and a net result of €61,887. Equity is growing by about 7.9% per year across the filed financial years. Its solvency ranks better than 84% of 22,679 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
05-01
financial year 2025 · micro format
2025
30-06
Financial
Highest result from 2019 to 2025net €61,887 ▲76.9%
Operating result €98,420, net result €61,887, both a record.
06-01
financial year 2024 · micro format
2024
05-01
financial year 2023 · micro format
2023
30-06
Financial
Equity above €500,000equity €521,357 ▲7.6%
A profit in every financial year since 2019 builds equity to €521,357.
04-01
financial year 2022 · micro format
2022
05-01
financial year 2021 · abbreviated format
2021
06-01
financial year 2020 · micro format
2020
06-01
financial year 2019 · micro format
2018
2017
03-01
financial year 2016 · abbreviated format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank